

file

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of:

Group Art Unit: To be assigned

BROWN et al.

Examiner: To be assigned

Appln. No.: 09/762,106

Filed: February 2, 2001

FOR: AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS

Date: August 20, 2001

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S.
patent applications:

Examiner's Initials	Inventor(s)	Application Number & Filing Date
	Brown et al.	09/508,055 March 7, 2000
	Hedge et al.	09/308,173
	Brown et al.	09/674,560 November 2, 2000
	Brown et al.	09/674,428 November 1, 2000
	Brown et al.	09/762,107 February 2, 2001
	Brown et al.	09/787,882 March 23, 2001
	Cumming et al.	09/787,883 March 23, 2001

BROWN et al. - U.S. Serial No.: 09/762,106

A copy of the specification, drawings and claims as currently pending is attached for each above-identified co-pending application.

The undersigned does not have immediate access to Application Serial No. 09/308,173. However, the undersigned understands that the text in this application is essentially the same as published PCT Application WO 98/22103, a copy of which is also provided herewith.

PLEASE DO NOT PRINT the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Attached is a Form PTO-1449 listing the enclosed documents.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee is under 37 CFR §1.17(p) is required.

BROWN et al. - U.S. Serial No.: 09/762,106

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.


Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 009901/0276502 and proceed to consider this IDS.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Respectfully Submitted,

PILLSBURY WINTROP LLP

By:


Donald J. Bird
Registration No. 25,323
Tel. No.: (703) 905-2018
Fax No.: (703) 905-2500

1600 Tysons Boulevard
McLean, Virginia 22102
Telephone: (703) 905-2000
DJB:mk